Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objective: Researchers have shown significant interest in cancer stem cells in recent years. CD44, CD24, CD133, and ALDH serve as indicators of cancer stem cell-like cells in Oral Squamous Cell Carcinoma. However, the prognostic significance of these Cancer Stem Cell markers in Squamous Cell Carcinoma is still debated. This study employed meta-analysis to evaluate the prognostic significance of cancer stem cells about Oral Squamous Cell Carcinoma.
Methods: CD44, CD133, CD24, and ALDH markers were analyzed in 19 retrospective studies to determine their relationship with prognosis and clinicopathological parameters. Risk ratios (RRs) and odds ratios (ORs) were calculated for 3-years survival rates and clinicopathological parameters, respectively, using a fixed-effects model.
Result: The finding of our study based on extracted survival rates showed that cancer stem cell markers, CD133 expression was related with the poor prognosis (RR= 1.62 ,95% CI = 1.08-2.44, P= 0.02). ALDH expression significantly correlated with lymph node metastasis (OR= 4.13, 95% Cl= 1.88-9.10, P<0.001) and clinical staging (OR= 2.26, 95% CI= 1.05-4.88, P= 0.04).
Conclusion: The findings indicate that CSC markers could be used to predict oral cancer prognosis. Our study contributes to the literature on survival outcomes of Oral Squamous Cell Carcinoma. These findings offer a structure for the advancement of cancer treatments that specifically target cancer stem cells. Conducting additional studies with a broader group of patients will help confirm the role of cancer stem cells as dependable predictors of prognosis.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11711375 | PMC |
| http://dx.doi.org/10.31557/APJCP.2024.25.10.3597 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Microfluidic synthesis of iron oxide nanoparticles for highly efficient intracellular delivery in stem cells and cancer cells.
Lab Chip
September 2025
Department of Engineering Design, Indian Institute of Technology Madras, India.
Microfluidic devices offer more accurate fluid flow control and lower reagent use for uniform nanoparticle synthesis than batch synthesis. Here, we propose a microfluidic device that synthesizes uniform iron oxide nanoparticles (IONPs) for highly efficient intracellular delivery. The 3D-printed device was fabricated, comprising two inlets in the T-shaped channel with an inner diameter of 2 mm, followed by a helical mixing channel with a single outlet.
View Article and Find Full Text PDFHIV-Associated Lymphomas: Updates from Pathogenesis to Treatment Strategies.
Curr HIV Res
September 2025
Department of Hematology-Oncology, Chongqing University Cancer Hospital, Chongqing 400030, China.
HIV-associated lymphoma (HAL) is an aggressive malignancy directly linked to HIV infection and accounts for more than 30% of cancer-related deaths in people living with HIV (PLWH). HAL subtypes, including diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), primary effusion lymphoma (PEL), and plasmablastic lymphoma (PBL), exhibit five to ten times higher incidence rates and distinct molecular profiles compared to HIV-negative lympho-mas. Pathogenesis involves HIV-driven CD4+ T-cell depletion, chronic B-cell activation, and on-cogenic viral coinfection.
View Article and Find Full Text PDFHow I treat Ph+ acute lymphoblastic leukemia.
Future Oncol
September 2025
Division of Leukemia, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) is characterized by the fusion gene which produces a constitutively active tyrosine kinase which drives disease pathogenesis and is associated with resistance to conventional chemotherapy. Intensive cytotoxic chemotherapy followed by allogeneic hematopoietic stem cell transplantation (HSCT), the historical treatment paradigm for Ph+ ALL, was associated with poor outcomes. The introduction of inhibitors of ABL1 revolutionized the treatment of Ph+ ALL.
View Article and Find Full Text PDFMultiple Hematopoietic Stem Cell Transplantations in Pediatric Acute Myeloid Leukemia: Prognostic Significance of Remission and Severe Sinusoidal Obstruction Syndrome.
Pediatr Blood Cancer
September 2025
Acute Myeloid Leukemia Sub-Committee, Association of Childhood Leukemia Study (JACLS), Japan.
Background: Relapsed or refractory cases of pediatric acute myeloid leukemia (AML) have poor outcomes despite advancements in chemotherapy and hematopoietic stem cell transplantation (HSCT). While a second HSCT is often a salvage option, its outcomes vary widely, and prognostic factors remain unclear.
Objectives: This study aimed to evaluate outcomes and identify prognostic factors in pediatric patients with AML who underwent multiple HSCTs.
Adoptive cellular therapies in multiple myeloma.
Best Pract Res Clin Haematol
September 2025
Department of Personalized Medicine and Rare Diseases, Medfuture Institute for Biomedical Research - Department of Hematology, Iuliu Hațieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania; Department of Hematology, Ion Chiricuta Cancer Center, Cluj Napoca, Romania. Electronic address:
Plasma cell myeloma (multiple myeloma) is a blood cancer characterized by the clonal proliferation of plasma cells in the bone marrow. Treatment strategies evolve year by year, new drugs getting Food and Drug Administration (FDA)-approved each year. Chimeric antigen receptor (CAR) therapies are an advanced form of immunotherapy that engineer T cells to recognize and destroy cancer cells.
View Article and Find Full Text PDF